A4 Amyloid Beta
Also known as: A4 Amyloid Beta, Amyloid Beta
A4 Amyloid Beta refers to the amyloid-beta peptide derived from the amyloid precursor protein and central to Alzheimer's disease research. It is used purely as a research reagent for neurodegeneration studies. This is a neurotoxic laboratory reagent intended strictly for in-vitro research; it is not for administration.
Last updated
Mechanism of Action
Amyloid-beta is generated by sequential beta- and gamma-secretase cleavage of the amyloid precursor protein (APP), producing peptides such as Abeta40 and the more aggregation-prone Abeta42. These monomers self-assemble into soluble oligomers and insoluble fibrils that deposit as the amyloid plaques characteristic of Alzheimer's pathology. Oligomeric amyloid-beta is implicated in synaptic dysfunction, oxidative stress, and neuroinflammation. As a research reagent, it is used to model aggregation kinetics and amyloid toxicity in vitro and in animal systems.
- Half-life
- Variable and context-dependent in experimental systems; not a dosed therapeutic
- Administration Routes
- subcutaneous
- Research Status
- Research Chemical
Reported Benefits
- Serves as a core research reagent for Alzheimer's disease modeling
- Enables study of amyloid aggregation and fibril formation
- Used to screen anti-amyloid compounds and aggregation inhibitors
- Supports investigation of synaptic toxicity mechanisms
- Standardizes neurodegeneration assays across laboratories
Potential Side Effects
- Neurotoxic in experimental systems by design
- Not intended for any administration to humans or animals therapeutically
- Aggregation-related handling variability in the lab
Common Dosing
Used at micromolar concentrations in cell-culture and biochemical assays per individual research protocols. This is laboratory reagent information only and not personal medical advice.
The dosing information above is aggregated from research literature and anecdotal community reports for educational purposes only. It is not a recommendation, prescription, or medical advice. Peptides are sold as research chemicals only and are not intended for human use.
Contraindications
- Not for human or therapeutic use
- Strictly a laboratory research reagent
- Neurotoxic and unsuitable for any in vivo dosing intent
Colivelin
Colivelin is a synthetic hybrid neuroprotective peptide that fuses activity-dependent neurotrophic factor (ADNF) with a potent Humanin derivative, studied for protecting neurons against amyloid-beta and other neurotoxic insults.
Humanin
Humanin is a mitochondrial-derived peptide studied for its cytoprotective, neuroprotective, and metabolic effects. The HNG (Humanin-G) analog is a more potent variant frequently used in research.
- View
The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor
1987
- View
Amyloid plaque core protein in Alzheimer disease and Down syndrome
1985
- View
The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics
2002
- View
Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory
2008